-- 蒙特利尔银行(BMO)在周三公布新房价格指数(NHPI)数据后表示,加拿大新房市场持续承压,3月份房价连续一年低于去年同期水平,凸显了这一趋势。 该银行指出,库存过剩与疲软的需求形成鲜明对比,尤其是在投资者市场,租金持续下跌。 BMO表示,政府近期出台了一些措施来应对市场。其中两项措施——包括扩大所有购房者(而不仅仅是首次购房者)的HST税收减免范围,以及降低开发费用——主要针对安大略省,该省是加拿大市场最疲软的地区之一。 该银行指出,它欢迎削减成本的举措,并预计这些举措最终将支持市场活动。不过,这两项措施都是暂时的,旨在解决目前积压的未售库存和未完工项目。 该银行补充说,从长远来看,人口结构、材料和劳动力供应等基本面因素将继续推动市场发展。 BMO 表示,当前经济疲软的积极一面是,它对消费者价格指数中的住房成本构成下行压力,抵消了伊朗战争带来的一些上行风险。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.